Brief: OSE Immunotherapeutics And Boehringer Ingelheim Present Positive Phase 1 Results With SIRPα Inhibitor BI 765063

Ose Immunotherapeutics SA

20/05/2021 06:40

May 20 (Reuters) - OSE IMMUNOTHERAPEUTICS SA  OSE.PA :
    * OSE IMMUNOTHERAPEUTICS AND BOEHRINGER INGELHEIM PRESENT
POSITIVE
PHASE 1 RESULTS WITH FIRST-IN-CLASS SIRPΑ INHIBITOR BI 765063 IN
ADVANCED SOLID TUMORS AT ASCO 2021
    * BI 765063, A FIRST-IN-CLASS SIRPΑ INHIBITOR ON SIRPΑ/CD47
"DON'T
EAT ME" PATHWAY, IS UNDER COLLABORATIVE DEVELOPMENT WITH
BOEHRINGER INGELHEIM
    * DATA INDICATE BI 765063 WAS WELL TOLERATED AND SHOWED
MONOTHERAPY ACTIVITY IN HEAVILY PRE-TREATED SOLID TUMOR PATIENTS

Source text for Eikon:  ID:nGNXDdLjY 
Further company coverage:  OSE.PA 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))